Why a glucagon receptor agonist in a weight-loss compound is not a contradiction posts 31–48

Fair, and the limits you put on it are the part I will remember.

The hepatic-steatosis rationale follows directly from glucagon receptor agonism promoting fat oxidation in the liver. Mechanistic plausibility in this field has a poor record of predicting clinical outcomes, which is why the trials matter more than the mechanism.

Reporting the observation and leaving the explanation open deliberately.

Narrowing post #30, because the general version has more than one answer.

The failure mode on glucagon receptor agonist is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

Glucagon receptor agonist is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.

Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.

Post #32 and I disagree about the size of the effect, not about the direction.

One more thing on glucagon receptor agonist that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.

Summarising the glucagon receptor agonist thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

This is the version I would want a new member to read first.

This follows post #38 rather than contradicting it.

Since glucagon receptor agonist keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

Worth separating two things that post #36 runs together.

The most useful reply I ever got about glucagon receptor agonist was a request to state my units. It sounds like pedantry and it has saved me twice.

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

Caveat: everything above assumes the paperwork is what it says it is.

Post #41 describes the usual case. This is about the unusual one.

Glycaemic effects improved rather than worsened in the diabetes work despite the glucagon component, which is the observation that resolves the apparent paradox. It is worth understanding that mechanism before repeating either half of it.

On identity confirmation more generally: for a compound with no widely available reference material, orthogonal confirmation matters more than usual. A mass result and a chromatographic result together say considerably more than either alone.